XVARY Composite Score
33
/ 100
Weak
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
It sells sensor gear, meters, filters, and installation services for homes and businesses.
How it gets paid
Last year Focus Universal made $398K in revenue. Ubiquitor wireless sensor devices was the main engine at $145K, or 36% of sales.
What just happened
Revenue hit $254K, and EPS stayed at -$0.17.
At a Glance
C++ balance sheet — some cracks in the foundation
50/100 earnings predictability — expect surprises
-$4.40 fy2024 eps est
~$398K fy2024 rev in feed
Operating margin not meaningful — tiny revenue, heavy losses
XVARY composite: 33/100 — weak
What They Do
It sells sensor gear, meters, filters, and installation services for homes and businesses.
There is no wide moat here. You have 46 employees and $398K of annual revenue. That is a public stock with private-company sales.
How They Make Money
$398K
annual revenue
Ubiquitor wireless sensor devices
$145K
USIP smart platform
$92K
Meters and light products
$68K
Filtration products
$53K
Integration and installation services
$40K
The Products That Matter
Wireless sensor platform
Ubiquitor
$145K · largest segment line
the segment table above puts Ubiquitor at $145K —about 36% of the $398K total. commercialization remains very early.
largest line item
Miscellaneous revenue line
Other Revenue
immaterial vs $398K
the five segment rows above sum to the $398K total—any immaterial “other” in filings is not broken out separately here. when the whole business is sub-$400K, there is no meaningful cushion hiding off-table.
no spare bucket
Key Numbers
$4.0M
market cap
You are paying about $10 for every $1 of sales. That is a tiny business price on a public stock.
$398K
annual revenue
That is the full-year sales base. It is one lost contract away from a bad year.
n/m
op margin
At ~$398K of sales, operating losses dominate—percentage margin is not a useful headline.
1.5
beta
Beta means stock swing versus the market. A 1.5 beta says your chart moves 50% harder than the average stock.
Financial Health
C++
Strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
C++ — below average. watch for debt servicing and cash burn.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
Revenue hit $254K, and EPS stayed at -$0.17.
Revenue rose 786% vs. prior year from a tiny base. Gross margin was 6.5%, so the business still has little room after product costs.
~$254K
rev (q)
-$0.17
eps (q)
6.5%
gross margin (q)
gross margin
The 6.5% gross margin is the real story because it leaves almost nothing after direct costs.
source: company earnings report
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is burning cash against a near-zero revenue base.
Med
Extreme cash burn
Heavy losses on ~$398K of trailing revenue mean losses are not a side effect. They are the story.
The new financing buys time, but it does not prove the operating model works.
Med
Tiny commercial base
Q3 2025 revenue was $30K, and the revenue lines shown on this page are measured in thousands, not millions.
When sales are this small, one delayed order or failed rollout can distort the entire quarter.
Med
Reliance on external funding
The $10.6M raise is now central to the investment case. That is useful in the short term, but it also means the business is leaning on capital markets rather than self-funded operations.
If the cash is spent without revenue scale showing up, shareholders are left with the same business and a weaker narrative.
Med
Bid-price compliance can return as a problem
The company recently regained compliance with Nasdaq's $1.00 minimum bid price requirement. That matters because the stock already had to solve it once.
Another slide toward that threshold would put listing status back in focus and make financing harder.
At ~$398K in trailing revenue and persistent losses, FCUV does not have much room for execution errors. The $10.6M raise changes the runway, not the economics.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Capital
What $10.6M actually buys
The raise is roughly 2.5x the market cap. If you own FCUV, this is the number that now matters most.
Revenue
Whether sales move beyond proof-of-concept size
Q3 revenue was $30K and trailing revenue on this page is ~$398K. You need that line moving up before the financing story fades.
Listing
Nasdaq bid-price risk
The company regained compliance with the $1.00 minimum bid rule. That issue is off the front page for now, not gone forever.
Next report
The next quarterly reset
With earnings predictability at 50/100, each report can rewrite the story fast. For a stock this small, one quarter can matter more than a full year does for a megacap.
Analyst Rankings
earnings predictability
50 / 100
middle of the road. in human-speak, the business is small enough that one contract or one miss can swing the quarter.
beta
1.5
Beta measures how much a stock moves versus the market. At 1.5, FCUV has historically moved more than the index.
price stability
5 / 100
That is very low. You are not buying steadiness here. You are buying exposure to sharp narrative shifts.
Source: institutional data
Institutional Activity
institutional ownership data for FCUV is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$6
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive